Sotrovimab Biosimilar, SARS-CoV-2 Spike Monoclonal Antibody

Additional Information:
C101P: Sotrovimab Biosimilar, SARS-CoV-2 Spike Monoclonal Antibody Recombinant Human IgG1 Kap|Human IgG1 kap|The anti-SARS-CoV-2 spike monoclonal antibody sotrovimab biosimilar was produced in the sotrovimab biosimilar CHO cells. |Specificity/Sensitivity: The sotrovimab biosimilar specifically binds to the spike protein of SARS-CoV-2. |Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological |0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives. |Purity: >95% by SDS-|The research grade sotrovimab biosimilar is shipped with ice |Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied. |Background What is sotrovimab biosimilar research grade? Sotrovimab is an Fc-engineered human monoclonal antibody directed against the spike protein of SARS-CoV-2. sotrovimab is a human monoclonal antibody (IgG1κ isotype). sotrovimab biosimilar uses the same protein sequences as the therapeutic antibody sotrovimab. sotrovimab/imdevimab is a combination medicine used for the treatment and prevention of COVID-19. It consists of two human monoclonal antibodies, sotrovimab and imdevimab that must be mixed together and administered as an infusion or subcutaneous injection. The combination of two antibodies is intended to prevent mutational escape. sotrovimab and imdevimab bind distinct epitopes on the RBD with dissoc constants KD of 46 and 47 pM, respectively. Please contact us if you are interested in the anti-SARS-CoV-2 spike monoclonal antibody imdevimab biosimilar. Syd Labs also provides the following research grade anti-SARS-CoV-2 spike antibody biosimilar proteins: Casirivimab biosimilar, research grade, SARS-CoV-2 spike monoclonal antibody